Aytu Biopharma (AYTU) Other Non-Current Liabilities (2015 - 2026)
Aytu Biopharma (AYTU) posted quarterly Other Non-Current Liabilities of $4.8 million for Q1 2026, up 17.41% year-over-year from $4.1 million in Q1 2025, and down 82.28% quarter-over-quarter from $27.3 million in Q4 2025.
Aytu Biopharma (AYTU) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Other Non-Current Liabilities for 12 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 17.41% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (up 17.41% YoY), while the FY2025 annual figure was $4.9 million, up 8.59% from the prior year.
- Other Non-Current Liabilities eased to $4.8 million in Q1 2026 per AYTU's latest filing, from $27.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $27.3 million in Q4 2025 and bottomed at $1.6 million in Q1 2023.
- Historically, Other Non-Current Liabilities has averaged $7.3 million across 5 years, with a median of $5.6 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 1646.61% — and 2023, when it tumbled 71.63%.
- Aytu Biopharma's Other Non-Current Liabilities stood at $9.8 million in 2022, then plunged by 35.14% to $6.3 million in 2023, then increased by 0.66% to $6.4 million in 2024, then soared by 328.08% to $27.3 million in 2025, then slumped by 82.28% to $4.8 million in 2026.
- Business Quant data shows AYTU's Other Non-Current Liabilities at $4.8 million in Q1 2026, $27.3 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.84 Mn |
| Dec 31, 2025 | 27.34 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2025 | 4.92 Mn |
| Mar 31, 2025 | 4.13 Mn |
| Dec 31, 2024 | 6.39 Mn |
| Sep 30, 2024 | 4.92 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 5.79 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Sep 30, 2023 | 8.11 Mn |
| Jun 30, 2023 | 6.98 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Dec 31, 2022 | 9.78 Mn |
| Sep 30, 2022 | 5.56 Mn |
| Jun 30, 2022 | 12.80 Mn |
| Mar 31, 2022 | 5.58 Mn |
| Dec 31, 2021 | 560,000.00 |
| Sep 30, 2021 | 319,000.00 |
| Jun 30, 2021 | 18.48 Mn |